Clinical manifestations and treatment of mucopolysaccharidosis type i patients in Latin America as compared with the rest of the world

Journal of Inherited Metabolic Disease

Volumn 34, Issue 5, 2011, Pages 1029-1037

  Muñoz Rojas, María Verónica ^h   Bay, Luisa ^a   Sanchez, Luz ^b   Van Kuijck, Marcel ^c   Ospina, Sandra ^d   Cabello, Juan Francisco ^e,f   Martins, Ana Maria ^g  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b Hospital de Especialidades UMAE 25   (Mexico)

^c Genzyme Latin America Group   (Brazil)

^d UNIVERSIDAD DEL ROSARIO   (Colombia)

^e UNIVERSIDAD DE VALPARAÍSO   (Chile)

^f UNIVERSITY OF CHILE   (Chile)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORNEA DISEASE; DISEASE REGISTRY; DISEASE SEVERITY; ENZYME REPLACEMENT; GEOGRAPHIC DISTRIBUTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HURLER SCHEIE SYNDROME; HURLER SYNDROME; JOINT CONTRACTURE; KYPHOSIS; MAJOR CLINICAL STUDY; MUCOPOLYSACCHARIDOSIS; ONSET AGE; PHENOTYPIC VARIATION; PNEUMONIA; PREVALENCE; SCHEIE SYNDROME; SCOLIOSIS; SLEEP DISORDER; SNORING; SOUTH AND CENTRAL AMERICA; TONGUE SWELLING; TONSIL DISEASE; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; ENZYME REPLACEMENT THERAPY; FEMALE; GEOGRAPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDURONIDASE; INFANT; INFANT, NEWBORN; LATIN AMERICA; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS I; PHENOTYPE; REGISTRIES; TIME FACTORS; WORLD HEALTH; YOUNG ADULT;

EID: 82955237534     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9336-2     Document Type: Article

References (22)

1. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14: 485-498 (Pubitemid 351494741)
2. Boelens JJ, Wynn RF, O'Meara A et al (2007) Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 40: 225-233 (Pubitemid 47108465)
3. Clarke L, Wraith JE, Beck M et al (2009) Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123: 229-240
4. Cox-Brinkman J, Boelens JJ, Wraith JE et al (2006) Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 38: 17-21 (Pubitemid 43923084)
5. Dierenfeld AD, McEntee MF, Vogler CA, et al. (2010) Replacing the enzyme a-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2: 60-89
6. Gabrielli O, Clarke LA, Bruni S, CoppaGV(2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 125: e183-e187
7. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188 (Pubitemid 32064139)
8. Khanna G, Van Heest AE, Agel J et al (2007) Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 39: 331-334 (Pubitemid 46403923)
9. Martins AM, Dualibi A.P., Norato D et al (2009) Guidelines for the management of mucopolysaccharidosis type I. J Pediatr 155: S32-S46
10. Muenzer J, Wraith JE, Clarke LA (2009) Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123: 19-29
11. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, Vogelstein B (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 3421-3452
12. Pastores G, Arn P, Beck M et al (2007) The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab 91: 37-47 (Pubitemid 46550926)
13. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90: 171-180 (Pubitemid 46108607)
14. Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350: 1960-1969 (Pubitemid 38580199)
15. Terlato NJ, Cox GF (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med 5: 286-294 (Pubitemid 36998686)
16. Thomas JA, Jacobs S, Kierstein J, Van Hove J (2006) Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 29: 762
17. Thomas JA, Beck M, Clarke JTR, Cox GF (2010) Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 33: 421-427
18. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 3: 240-252
19. Vijay S, Wraith JE (2005) Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr 94: 872-877 (Pubitemid 41044770)
20. Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6: 489-506 (Pubitemid 40521085)
21. Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubleblinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144: 581-588 (Pubitemid 38594757)
22. Wraith EJ, Hopwood JJ, Fuller M, Meikle PJ, Brooks DA (2005) Laronidase treatment of mucopolysaccharidosis I. BioDrugs 19: 1-7 (Pubitemid 40432502)